Five years ago, Drs. Lee Cranmer, William Tap, and collaborators began an analysis on data collected during the SARC021 clinical trial. The goal was to analyze the impact of mode of doxorubicin administration on efficacy and adverse events in soft tissue sarcoma treatment; these results were published February 2023 in Clinical Cancer Research, linked here.
The data used for this analysis was pulled from SARC's Unified Data System (well-annotated repositories of research biospecimens, imaging, & data collected from more than two dozen SARC-sponsored/investigator-initiated clinical trials). For more information on UDS, and how to access, please click here.